Pituitary-hormone secretion by thyrotropinomas by Roelfsema, Ferdinand et al.
Pituitary-hormone secretion by thyrotropinomas
Ferdinand Roelfsema Æ Simon Kok Æ Petra Kok Æ Alberto M. Pereira Æ
Nienke R. Biermasz Æ Jan W. Smit Æ Marijke Frolich Æ Daniel M. Keenan Æ
Johannes D. Veldhuis Æ Johannes A. Romijn
Published online: 3 December 2008
 The Author(s) 2008. This article is published with open access at Springerlink.com
Abstract Hormone secretion by somatotropinomas, cor-
ticotropinomas and prolactinomas exhibits increased pulse
frequency, basal and pulsatile secretion, accompanied by
greater disorderliness. Increased concentrations of growth
hormone (GH) or prolactin (PRL) are observed in about
30% of thyrotropinomas leading to acromegaly or disturbed
sexual functions beyond thyrotropin (TSH)-induced hyper-
thyroidism. Regulation of non-TSH pituitary hormones in
this context is not well understood. We there therefore
evaluated TSH, GH and PRL secretion in 6patients with up-
to-date analytical and mathematical tools by 24-h blood
sampling at 10-min intervals in a clinical research labora-
tory. The proﬁles were analyzed with a new deconvolution
method, approximate entropy, cross-approximate entropy,
cross-correlation and cosinor regression. TSH burst fre-
quency and basal and pulsatile secretion were increased in
patients compared with controls. TSH secretion patterns in
patients were more irregular, but the diurnal rhythm was
preserved at a higher mean with a 2.5 h phase delay.
Although only one patient had clinical acromegaly, GH
secretion and IGF-I levels were increased in two other
patients and all three had a signiﬁcant cross-correlation
between the GH and TSH. PRL secretion was increased in
one patient, but all patients had a signiﬁcant cross-correla-
tion with TSH andshoweddecreased PRLregularity. Cross-
ApEn synchrony between TSH and GH did not differ
between patients and controls, but TSH and PRL synchrony
was reduced in patients. We conclude that TSH secretion by
thyrotropinomas shares many characteristics of other
pituitary hormone-secreting adenomas. In addition, abnor-
malities in GH and PRL secretion exist ranging from
decreased (joint) regularity to overt hypersecretion,
although not always clinically obvious, suggesting tumoral
transformation of thyrotrope lineage cells.
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Introduction
The major regulators of thyrotropin (TSH) secretion are
thyrotropin-releasing hormone (TRH), the inhibitory neu-
rotransmitters dopamine and somatostatin, and negative
feed back by thyroid hormones, thyroxine and triiodothy-
ronine [1]. The interplay among these regulators in time
dictates the TSH secretion pattern, which is characterized
by a diurnal variation of serum TSH concentrations with
superimposed (small) bursts. The 24-h secretion proﬁle of
TSH has been well described in various pathophysiological
conditions, including hyperthyroidism, hypothyroid-
ism, obesity, fasting and in non-thyroidal illness, but not
in detail in hyperthyroidism caused by a pituitary
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are relatively rare pituitary tumors (less than 1% of all
pituitary adenomas), and are usually diagnosed when the
TSH level is inappropriately elevated in a patient with
raised serum thyroxine levels, combined with the presence
of a pituitary (micro) adenoma [7]. In other hormone-
secreting pituitary adenomas, e.g. Cushing’s disease and
prolactinomas, hormone secretion is marked by diminished
or absent diurnal amplitude (one-half the difference
between maximal and minimal concentrations), increased
basal (i.e. non-pulsatile) secretion, elevated pulse fre-
quency and reduced secretory regularity [8–10].
By analogy with results obtained in other hormone-
secreting pituitary adenomas, we hypothesized that patients
with thyrotropinomas would display a blunted diurnal
secretion pattern, heightened basal and pulsatile TSH
release, increased pulse frequency and attenuated regular-
ity. Moreover, TSH adenomas may co-secrete other
pituitary hormones, most frequently growth hormone and
in decreasing order prolactin and gonadotropins, as well as
uncombined a-subunit [7]. To examine the mechanistic
secretory similarities between TSH and co-secreted hor-
mones, we quantitated correlations between hormone
concentration time series (TSH, GH, prolactin and a-sub-
unit) using selected model-free tools. Finally, many
patients with thyrotropinomas are currently treated with
slow-release somatostatin analog formulations. Therefore
we also explored the changes in fasting hormone levels in
patients treated with long-acting somatostatin analogs. To
this end serum hormone concentration proﬁles of six
patients with thyrotropinomas were compared with those of
18 healthy controls that were investigated in a strictly
comparable way.
Patients and methods
Six patients (4 m/2 f) with central hyperthyroidism caused
byaTSH-secretingadenomaand18healthynon-obese(BMI
18–25 kg/m
2) control subjects of similar sex (12 m/6 f) and
age distribution were enrolled in this study, after giving
written acknowledgment of informed consent for participa-
tion. All premenopausal controls were required to have a
regular menstrual cycle and not use oral contraceptives.
Female subjects were studied in the early follicular phase of
their menstrual cycle. Chronic disease, depression (present
or in history), smoking, recent transmeridional ﬂights, night
shift work, weight change ([3 kg in 3 months), and use of
medication (except for the patients) were exclusion criteria.
All control subjects had an unremarkable medical history,
and no abnormalities were found during physical examina-
tion, standard laboratory hematology, and blood chemistry
and urine tests.
Clinical protocol
The protocol was approved by the Medical Ethics Com-
mittee of the Leiden University Medical Center (Leiden,
The Netherlands). Subjects were admitted to the Clinical
Research Unit of the Department of Internal Medicine. A
cannula for blood sampling was inserted into an antecubital
vein. The cannula was attached to a three-way stopcock
and kept patent by a continuous saline infusion. Blood
samples were taken at 10-min intervals for determination
of plasma TSH, GH, prolactin and a-subunit concentra-
tions. Subjects remained recumbent, except for bathroom
visits. No daytime naps were allowed. Meals were served
according to a ﬁxed time schedule. Lights were switched
off at 2300 h. Vital signs were recorded at regular time
intervals, and great care was taken not to disturb patients
while sampling blood during their sleep (no electroen-
cephalography sleep recording was performed).
Assays
Samples were centrifuged at 4000 rotations/min at 4C for
20 min, within 60 min of sampling. Subsequently, plasma
was divided into separate aliquots and frozen at -80C until
assays were performed. Samples of each subject were
determined in the same assay run. Plasma TSH concentra-
tions were measured with a time-resolved immunoﬂu-
orometric assay (Wallac, Turku, Finland), and its standard
was calibrated against the World Health Organization sec-
ond standard International Reference Preparation (80/558)
hTSH for immunoassays. The limit of detection was
0.05 mU/liter,andtheinterassaycoefﬁcientofvariationwas
less then 5%. Free T4 (fT4) was estimated using an auto-
mated system (Elecsys 2010, Roche Diagnostics Nederland
BV, Almere, Netherlands). Triiodothyronine was measured
with Abbott Axsym (Abbott Park, IL).
GH was measured with a sensitive time-resolved ﬂuoro-
immunoassay (Wallac Oy, Turku, Finland). The assay is
speciﬁc for the 22 kDa GH. The standard was biosynthetic
recombinant human GH (Genotropin, Pharmacia & Up-
john, Uppsala, Sweden), and was calibrated against the
WHO First International Reference Preparation 80/505 (to
convert lg/l to mU/l multiply by 2.6). The limit of detec-
tion of this assay (deﬁned as the value 2SD above the mean
value of the zero standards) was 0.01 mU/l (0.0038 ng/ml).
The intraassay coefﬁcient of variation varied between 1.6
and 8.4% in the range from 0.01 to 18 lg/l and interassay
coefﬁcient of variation was 2.0–9.0% in the same range.
Total IGF-I was determined by RIA (Incstar, Stillwater,
MN) after extraction and puriﬁcation on ODS-silica col-
umns. The intraassay coefﬁcient of variation was less than
11%. The detection limit was 1.5 nmol/l. Age-related
normal data were determined in the same laboratory.
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tive time-resolved ﬂuoroimmunoassay with a detection
limit of 0.04 lg/l (Delﬁa, Wallac Oy, Turku, Finland). The
intra-assay coefﬁcient of variation varied from 2.0 to 3.3%
and inter-assay coefﬁcient of variation is 3.4–6.2%, in the
concentration range from 3.0 to 80 lg/l.
The a-subunits were measured by an immunoradiomet-
ric assay (Immunotech, Marseille, France). The assay is
calibrated with WHO International Reference Preparation
75/569, and 1 mU is equivalent to 1 lg. The intra-assay
coefﬁcient of variation was 6.8% and the inter-assay
coefﬁcient of variation 9.1% in the concentration range
observed here.
Calculations and statistics
Deconvolution analysis
Each hormone concentration time series was analyzed using
a recently validated deconvolution method [11]. The auto-
mated Matlab program ﬁrst detrends the data and
normalizes concentrations to the unit interval [0, 1]. Sec-
ond, successive potential pulse-time sets, each containing
one fewer burst, are created by a smoothing process (a
nonlinear adaptation of the heat-diffusion equation). Third,
a maximum-likelihood expectation (MLE) deconvolution
method estimates all secretion and elimination rates
simultaneously for each candidate pulse-time set. The
deconvolution model speciﬁes basal secretion (b0), two
half-lives (a1, a2), an accumulation process and weak in-
terpulse length dependency for secretory-burst mass (g0,
g1), random effects on burst mass (rA), procedural and
measurement error (re), and a 3-parameter secretory-burst
waveform (b1, b2, b3). Model selection is performed to
distinguish among the candidate pulse-time sets using the
Akaike information criterion [12]. Observed interpulse
intervals are described by a 2-parameter Weibull process
(more general form of a Poisson renewal process). The
parameters (and units) are frequency (number of bursts per
unit time, lambda of Weibull distribution), regularity of
interpulse intervals (unitless gamma of Weibull), slow half-
life (min), basal and pulsatile secretion rates (concentration
per unit time), mass secreted per burst (concentration), and
waveform mode (time delay to maximal secretion after
burst onset, min) [11].
Approximate entropy (ApEn)
Approximate entropy, ApEn, is a scale-and model-inde-
pendent univariate regularity statistic used to quantitate the
orderliness (subpattern consistency) of serial stationary
measurements [13, 14]. Mathematical models and feedback
experiments establish that pattern orderliness monitors
feedback and/or feedforward interactions within an inter-
linked axis with high sensitivity and speciﬁcity, both[90%
[15]. Reduced pattern regularity typiﬁes hormone secretion
in puberty and aging, during diminished negative feedback
or ﬁxed exogenous stimulation, and by autonomous neuro-
endocrine tumors [16, 17]. Data are presented as normalized
ApEn ratios, deﬁned by the mean ratio of absolute ApEn to
that of 1000 randomly shufﬂed versions of the same series.
ApEn ratios close to 1.0 express high irregularity (mean
randomness) of pulsatile hormone patterns.
Cross-Approximate Entropy (X-ApEn) is a scale- and
model-independent two-variable regularity statistic used to
quantitate the relative pattern synchrony of coupled time
series [18, 19]. Clinical experiments establish that changes
in two-hormone synchrony monitor feedback and/or feed-
forward adaptations within an interlinked axis with high
sensitivity and speciﬁcity [15]. To normalize comparisons
among subjects, X-ApEn is computed on the paired origi-
nal time series (observed X-ApEn) and then recalculated
1000 times after each series in a pair is shufﬂed randomly
[rearranged in order or sequence without replacement or
loss (random X-ApEn). Repetition of the permutation
procedure allows calculation of the maximum, mean, and
SD of random X-ApEn for a given series length and assay
pair. A normalized distributional measure is then the
number of SDS (z scores) separating observed from the
maximum or mean random X-ApEn. Higher absolute z
scores denote more synchronous patterns. Lower X-ApEn
ratios and higher absolute z scores denote greater pattern
synchrony between (coordinate control of) the interlinked
signals. Reduced regularity of hormone secretion typiﬁes
puberty, aging, diminished negative feedback due to target-
gland failure, ﬁxed exogenous stimulation, and autono-
mous neuroendocrine tumors [20, 21].
Diurnal rhythmicity
Nyctohemeral variation of TSH concentrations was deter-
mined by a nonlinear unweighted least-squares cosine
regression, as reported earlier [22]. Ninety-ﬁve percent sta-
tistical conﬁdence intervals were determined for the 24-h
cosineamplitude(50%ofthezenith-nadirdifference),mesor
(rhythmic mean) and acrophase (clock time of maximal
value).
Statistics
Data are presented as mean ± SEM, unless otherwise
speciﬁed. Means of TSH concentration and secretion
parameters of both groups were compared using two-tailed
independent Student’s t-test after logarithmic transforma-
tion or with the Kolmogorov–Smirnov two-sample test.
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centration series were calculated after prewhitening of the
series by ﬁrst differencing in order to prevent spurious
correlations. Statistical calculations were performed with
Systat software, version 11 (Systat Inc, San Jose, CA).
Signiﬁcance level was set at 0.05.
Clinical presentation of the patients
Patient1wasstudiedwhenhewas73 yearsold.Hismedical
historyrevealed thatheunderwentthyroid surgery attheage
of 53 yr because of presumed hyperthyroidism. After sur-
gery he developed visual complaints and headaches and he
was diagnosed with a large pituitary adenoma. He under-
went pituitary surgery and because of incomplete resection
pituitary irradiation as well. He was treated with thyroxine,
testosterone supplements and cortisone acetate. For the
pituitary tumor residue he received ﬁrst bromocriptine, and
later when immunostaining revealed b-TSH, short-acting
octreotide, 100 lg t.i.d. The 24-h blood sampling study was
performed after withholding octreotide for 4 weeks. He is
currently treated with octreotide-LAR, hydrocortisone,
thyroxine and testosterone replacement.
Patient 2, aged 44 years was referred of acromegaly and
central hyperthyroidism. After detailed clinical studies and
pretreatment with sc octreotide (100 lg t.i.d.) he underwent
transsphenoidal adenomectomy leading to biochemical cure
of the central hyperthyroidism, but insufﬁcient control of
GH secretion. He is currently treated with octreotide only.
Patient 3, aged 38 years was evaluated at a teaching
hospital because of weight loss and nervous symptoms. She
was hyperthyroid, but TSH levels were not suppressed and
MRI of the pituitary gland revealed a macroadenoma. For
detailed endocrine studies she was referred to the Leiden
University Medical Center. Subsequently, she was treated
with octreotide LAR, with a favorable clinical response.
After one year of treatment the 24-h blood sampling study
was repeated.
Patient 4, aged 26 years was referred because of
long-standing nervousness, palpitations and excessive
perspiration. He appeared to be hyperthyroid with non-
suppressed TSH levels. Further studies revealed a pituitary
adenoma and detailed biochemical studies, including a 24-
h blood sampling were carried out. He was treated with
octreotide LAR with good clinical response. After 3 years
he underwent a repeat 24-h blood sampling study.
Patient 5, aged 61 years was referred because of central
hyperthyroidism and a pituitary microadenoma. Detailed
biochemical studies were carried out, including a 24-h
blood sampling. The patient, however, refused treatment.
During infrequent follow-up visits for the last 12 years his
clinical condition and TSH and thyroid hormone levels
remained unchanged.
Patient 6, aged 60 years was medically treated in 1998
for hyperthyroidism in another hospital for one year. In
2006 she was reevaluated because of persisting hyper-
thyroid complaints, which were conﬁrmed by biochemical
analyses. In addition, the TSH levels were non-sup-
pressed and the MRI of the pituitary gland revealed a
macroadenoma. After the endocrine studies in our facil-
ity, treatment with octreotide LAR 20 mg was started.
However, although TSH concentration decreased, T4
levels remained elevated, so that after 3 months the
octreotide dose was increased to 30 mg/4 weeks without
a clinical satisfactory response. Subsequently, it was
found that she had a toxic nodular hyperthyroidism as
well, for which was recently treated with strumazol and
radioactive iodine (613 Mbq). Because of atrial ﬁbrilla-
tion she was put on anticoagulant therapy and octreotide
LAR was withheld.
Clinical and biochemical details of the patients are
displayed in Table 1. One patient had severe acromegaly,
and two other patients had slightly elevated IGF-I
concentrations.
Results
Results of the i.v. 200 lg TRH test are shown in Fig. 1.
Without exception the TSH increase was subnormal,
Table 1 Clinical characteristics of the patients
Patient Gender Age fT4
(nmol/l)
T3
(nmol/l)
TSH
(mU/l)
a-Subunit/TSH
molar ratio
Thyroid
size
Pituitary MRI Immunostaining
adenoma
1 Male 73 31 n.d. 4.30 3.99 Enlarged Macroadenoma TSH ?
2 Male 44 47 4.1 3.01 7.80 Enlarged Macroadenoma GH/TSH ?/?
3 Female 38 36 3.2 1.40 1.30 Enlarged Macroadenoma n.a
4 Male 26 30 4.2 3.35 0.93 Enlarged Macroadenoma n.a
5 Male 61 34 3.3 5.84 0.62 Enlarged Microadenoma n.a
6 Female 60 38 3.2 1.01 14.1 Enlarged Macroadenoma n.a
Normal range (median) for fT4: 10–24 (16.0) nmol/l, normal range for T3 1.1–3.0 (2.1) nmol/l, normal range for TSH 0.72–2.99 (1.25) mU/l.
n.d. not determined, n.a. not applicable
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exceeding 100%). An octreotide test (50 lg i.v.) was per-
formed in 4 patients and the results are shown in Fig. 1.
Acute inhibition of serum TSH concentration was
remarkably similar among patients with a mean of 56%,
ranging from 52 to 65%.
Serum TSH concentration proﬁles of the 6 investigated
patients are shown in Fig. 2 with the 95% conﬁdence
interval for TSH proﬁles of non-obese controls. Results of
the deconvolution analysis and of approximate entropy of
the TSH concentration proﬁles are shown in Fig. 3. TSH
secretion in thyrotropinoma patients was characterized by
increased hormone burst frequency. Furthermore, basal and
pulsatile TSH secretion was increased in patients, but the
secretion-burst shape (waveform) was unchanged, as indi-
cated by the mode. TSH secretory regularity of the
subordinate patterns in patients was markedly decreased
(increased ApEn ratio). Regularity of the interburst inter-
vals however, was unchanged as demonstrated by the
Weibull gamma results.
The estimated ﬁrst component of the TSH half-life did
not differ in patients and controls (24.5 ± 2.5 vs.
22.2 ± 2.2 min), but the slow component was shorter in
patients (87.9 ± 10.7 vs. 108 ± 4.3 min, P = 0.048). This
could denote reduced sialylation of tumoral TSH.
With the exception of one patient, GH secretion as also
analyzed. The results are summarized in Table 2 and the
GH concentration proﬁles are displayed in Fig. 4. Serum
IGF-I concentrations and standard deviation scores were
increased in patients 1–3, of whom only patient 2 had
clinically active disease. However, patients 1 and 3 had
(slightly) increased GH secretion, with respect to age and
both had a deﬁnitely abnormal GH secretion proﬁle,
compared with the other two patients and examples of
healthy controls (Fig. 4). Approximate entropy for GH
secretion was only increased in the patient with active
acromegaly.
Serum prolactin concentration proﬁles are displayed in
Fig. 5. One patient (#3) had increased levels throughout the
24-h cycle, and two others had raised levels during the
daytime. In contrast, the irradiated patient had subnormal
levels. The regularity of PRL patterns in patients was
diminished compared with controls, as deﬁned by higher
ApEn ratios in patients (0.788 ± 0.074, mean ± SD) than
controls (0.461 ± 0.131, P\0.001).
We also investigated cross-correlations between 24-h
TSH concentrations and each of GH, a-subunit and PRL.
Proﬁles of the serum concentrations of GH and TSH in two
patients were rather similar, as illustrated in Fig. 6. The
cross-correlation outcomes are shown in Table 3. Three
patients had a highly signiﬁcant correlation between serum
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Fig. 1 Serum TSH response to 100 lg TRH. Note the subnormal
response in all patients (Left panel). Effect of intravenous octreotide
injection on TSH concentrations. Note the logarithmic scale of the
abscissa (Right panel)
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Fig. 2 Serum TSH concentration proﬁles of 6 patients with a
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interval of 18 healthy matched control subjects
T
S
H
 
s
e
c
r
e
t
i
o
n
 
(
m
U
/
l
/
2
4
h
)
0
10
20
30
40
50
60
70
patients
controls basal p=0.02
pulsatile p=0.04
total  p=0.01
P
a
r
a
m
e
t
e
r
0
10
20
30
40 pulse frequency
(no/24h) p=0.001
mode (min)
p=0.70
Weibull lambda
(no/24h), p=0.001
Approximate Entropy
0.0
.2
.4
.6
.8 p=0.01
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123TSH and GH concentrations. In contrast, in healthy con-
trols no correlation between these two hormones could be
demonstrated. In two of 5 patients a signiﬁcant correlation
could be demonstrated between serum TSH and a-subunits
concentrations, where an almost 100% concordance was
expected when a-subunits are truly co-secreted with TSH.
Unfortunately, we have no comparable data in controls
subjects. The cross-correlation between TSH and prolactin
was signiﬁcant in all patients. However, two-thirds of
Table 2 Growth hormone secretion in thyrotropinoma
Patient Age (years) Sex Fasting GH (mU/l) GH secretion
(mU/l/24 h)
IGF-I (lg/l) IGF-I SDS ApEn ratio
1 73 Male 2.0 169 228 3.00 0.483
2 44 Male 142 17070 550 10.4 0.787
3 38 Female 1.90 205 274 2.23 0.433
4 26 Male 0.11 174 144 0.02 0.310
5 61 Male 0.20 n.d. 182 1.80 n.d.
6 60 Female 2.50 81 135 1.16 0.480
Controls 30–68 (49) Male 0.02–1.10 (0.18) 116–200 (45) 75–185 (107) – 0.181–0.558 (0.330)
Controls 21–70 (37) Female 0.06–2.80 (0.56) 57–247 (123) 87–234 (143) – 0.260–0.514 (0.380)
GH secretion was calculated with deconvolution of the 24 h serum GH concentration proﬁles. Control values were obtained from 26 male and 22
female healthy subjects, who were investigated in a similar way. Data for controls are shown as the range and median. n.d. not determined, SDS
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Fig. 4 Serum GH concentration proﬁles of 5 patients with a
thyrotropinoma and 2 healthy representative controls (left upper
panel, continuous line male subject, dashed line female subject). Note
the difference in scales of the abscissa. The GH secretion patterns of
patients #1–3 are clearly abnormal, while that of patient #6 only
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Fig. 6 TSH and GH proﬁles of 2 patients with a thyrotropinoma.
Note the similarity of the patterns of both hormones
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123healthy controls also showed a signiﬁcant correlation
between these two hormones, with a median correlation
coefﬁcient of 0.300, range 0.176–0.360.
Cross-ApEn ratios for TSH and GH were similar in
patients and controls (0.716 ± 0.085 in patients vs.
0.678 ± 0.018 in controls), but cross-ApEn ratios for TSH
and prolactin were increased in patients (0.774 ± 0.041 vs.
0.547 ± 0.022, P = 0.001), denoting signiﬁcant loss of
pattern synchrony.
AllpatientshadsigniﬁcantdiurnalTSHandPRLrhythms.
For TSH the acrophase of the rhythm was shifted (time-
delayed) from 2.83 to 5.58 h (P = 0.02) and for PRL from
4.36 to 6.20 h (P = 0.07). For TSH amplitudes were
0.83 ± 0.29 mU/l in patients and 0.54 ± 0.25 mU/l in con-
trols (mean ± SD, P = 0.09),and for PRL 1.43 ± 0.44 lg/l
and 0.97 ± 0.60 lg/l, respectively (P = 0.09).
Effect of octreotide treatment
Five of the six patients received octreotide as medical
treatment, 4 as octreotide LAR. One patient (#5) refused
medication. One other patient (#1) was treated preopera-
tively with octreotide (200 lg t.i.d.) for 3 months.
Subsequently, he underwent transsphenoidal surgery, but
had still (slightly) increased GH and IGF-I concentrations
afterwards although TSH and thyroid hormone concentra-
tions became and remained normal. This patient was
treated with octreotide for the persisting GH excess.
Finally, patient #6 had also a toxic nodular goiter, for
which she was treated with radioactive iodine and sup-
pressive thyroid medication after initial failure of
normalization of thyroid hormone concentrations associ-
ated with (moderate) decrease of already low TSH levels.
The effect of octreotide on fasting morning thyroxine,
TSH, GH, IGF-I, prolactin and a-subunit concentrations is
shown in Fig. 7. Free thyroxine concentrations normalized
in all but one with a parallel reduction of TSH and also of
IGF-I, GH and prolactin concentrations. The size of the
adenoma on MRI decreased slightly in patients #3 and 4,
but remained unchanged in patients #2 and 6.
Discussion
This cohort of patients with a TSH-secreting pituitary
adenoma maintained a high TSH pulse frequency with
normal pulsing variability, increased basal and pulsatile
TSH release and decreased secretory-pattern regularity. In
addition, three of ﬁve patients also showed increased GH
secretion, although clinically manifest in only one. Sus-
tained increased PRL levels were present in one patient.
Previous investigations have demonstrated that fre-
quent hormone pulses constitute feature of all endocrine
adenomas, including somatotropinomas, prolactinomas,
corticotropinomas and also hormone-secreting adrenal
adenomas [8–10, 17]. This common ﬁnding among diverse
tumors suggests that the cause of increased pulsatility is not
primarily mediated via signaling of increased frequency of
stimulatory peptides or neurotransmitters, but rather is an
intrinsic feature of the adenoma per se.
Stability of the Weibull gamma parameter indicated that
the increased TSH pulse frequency in patients is not
associated with altered variability in length of interpulse
intervals. Conversely, the elevated Weibull lambda
parameter conﬁrms increased TSH pulsing. The other
remarkable ﬁnding was the decreased regularity of TSH
secretory patterns as revealed by the increased ApEn.
Approximate entropy has been investigated in a variety of
altered feed-forward and feed-back states in healthy indi-
viduals, for instance in the somatotropic axis in healthy
subjects during GHRH or GHRP-2 infusions and pegvi-
somant administration [23–25]. Increased stimulation of
somatotropes is accompanied by decreased regularity
(increased ApEn), and decreased IGF-I feedback by
blocking the GH signal with the GH-receptor blocking
Table 3 Cross-correlations between TSH, GH and a-subunits in
thyrotropinoma
Patient TSH/GH TSH/a-subunits TSH/prolactin
1 0.337 ± 0.083 n.s. 0.350 ± 0.083
2 0.345 ± 0.084 0.427 ± 0.084 0.428 ± 0.083
3 0.279 ± 0.084 n.s. 0.190 ± 0.085
4 n.s. 0.320 ± 0.121 0.385 ± 0.083
6 n.s. n.s. 0.405 ± 0.083
Cross-correlations were calculated after removing autocorrelations by
ﬁrst differencing. n.s. non-signiﬁcant
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Fig. 7 Effect of octreotide treatment on fasting morning hormone
concentrations in 5 patients with a thyrotropinoma. fT4 denotes serum
free thyroxine. Note the logarithmic scale for GH
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123drug, pegvisomant, is also associated with decreased
orderliness of GH secretion. Such studies indicate that
higher ApEn reﬂects elevated feed-forward and reduced
feed-back signaling of the studied system [15, 25]. For
TSH comparable conditions of diminished feedback would
be primary hypothyroidism and thyroid hormone resis-
tance, which have not been studied. In contrast, endocrine
tumors are generally not well regulated by exogenous
stimuli (with the possible exceptions of some GHRH-
secreting carcinoid tumors and ectopic CRH-producing
tumors), although diminished feedback may be present, as
observed in corticotropinomas (glucocorticoids), somato-
tropinoma (IGF-I) and parathyroid adenomas (calcium).
Thus, increased TSH ApEn in thyrotropinomas likely
reﬂects disorganized secretion from the tumor per se.
Aberrant alternative splicing of thyroid hormone-receptor
b2 mRNA encoding a thyroid hormone receptor variant
lacking T3 binding activity might in principle also con-
tribute to irregular secretion [26, 27].
Co-secretion of GH and prolactin is found in about one-
third of patients with a thyrotropinoma [7]. Up to 16% of
patients co-secrete GH and 11% prolactin, while co-
secretion of gonadotropins is rare (about 1%). Immuno-
histochemical studies report an even larger incidence of
co-expression of GH and PRL mRNA in the thyrotrope
tumors, suggesting that either these hormones are not
secreted in quantities leading to clinical disease and fur-
thermore that the tumor cell is derived from a common
precursor cell [28–31].
Although all patients with a TSH-secreting adenoma
secrete relatively excessive amounts of thyroid hormones,
the TSH concentration in patients varies from normal to
grossly elevated, in contrast with other hormone-secreting
pituitary adenomas, e.g. somatotropinomas and cortico-
tropinomas. This observation has been explained by
increased biological activity of less acidic post-glycosyla-
tion isoforms of TSH [32]. Some preservation of feedback
at the pituitary level cannot be ruled out, although it has not
been studied in detail. Indeed, in our case series only two
patients had an increased mean TSH concentration (Fig. 2),
although the other patients should have had suppressed
TSH levels due to elevated T4 (T3) concentrations. Ter-
minal sialylation of TSH can reduce its metabolic
clearance, and indeed we found a 25% increase of the
second component of the TSH half-life in our patients.
The other major cause of central hyperthyroidism is
thyroid hormone resistance. This syndrome isnot associated
with a pituitary tumor [33]. The TRH test in this condition is
normal or hyperresponsive in contrast to the blunted TSH
response in thyrotropinomas. In addition, patients with this
disorder do not respond to somatostatin analog therapy [34].
The results of the TRH and octreotide tests are relevant and
important in this context, because we have no histological
proof for a thyrotropinoma in 4 of the 6 patients, although
the presence of a (micro) adenoma would not favor a
resistance syndrome. Other indirectmethods to discriminate
between thyroid hormone resistance and thyrotropinomas
are the dissociated effects of TRH on TSH and a-subunits
and the molar ratio of a-subunits and TSH. Taking into
account that one of the patients was postmenopausal
(although she had a normal a-subunit level) only two of our
patients had an increased ratio. However, recent data sug-
gest that high levels of a-subunit and an increased ratio are
not invariably present and are actually normal in 20% of
patients with a thyrotropinoma [1].
Treatment modalities of thyrotropinomas include trans-
sphenoidal surgery and/or (primary) medical treatment.
Generally, surgery may cure up to 50–80% and therapy with
long-acting somatostatin analogues may be effective in
about 80% of patients [35–41]. In line with the literature
fasting hormone levels (TSH, fT4, GH, IGF-I and prolactin)
decreased in all patients (except for T4 in the patient with a
toxic nodular goiter) during treatment with octreotide-LAR,
thus demonstrating that the suppressive effect was not
restricted to TSH secretion. Rare subjects have had both
primary hyperthyroidism and central hyperthyroidism [36,
42]. Indeed, medical therapy failure aimed at TSH nor-
malization may lead to the correct (additional) diagnosis.
A limitation of the study is the small number of inves-
tigated patients with this rare disorder. In addition, we
could only evaluate patients with TSH concentrations
mostly within the normal range. Therefore, the present
conclusions cannot be extrapolated to patients with much
higher TSH levels.
All our patients had a signiﬁcant diurnal TSH rhythm
withameanphasedelayof2.7 hwithunchangedamplitude.
Few TSH serum proﬁles of patients with TSH-secreting
adenomas have been published, but not of co-secreted GH
and prolactin. Samuels et al. described a female patient with
a TSH-secreting tumor, who had pulsatile TSH secretion,
but no diurnal rhythm when monitored by 15-min sampling
for 24-h [43]. Later, the same group reported absent diurnal
variation of TSH in two other thyrotropinoma patients [44].
In another report two male patients were sampled at 2-h
intervals: one patient showed a clear diurnal rhythm with a
signiﬁcant phase delay, as observed here, whereas the other
patient had no clear rhythm [45]. Finally, a male patient was
described with no apparent TSH rhythm, but the rhythm was
restored during treatment with bromocriptine and octreo-
tide. Paradoxically, the mean 24-h TSH concentration
increased during medical treatment [46].
This limited patient series also demonstrates abnormal-
ities in GH and prolactin secretion. One patient had overt
acromegaly, and two others exhibited a deﬁnitely abnormal
GH secretion pattern (Fig. 5), which resembled the TSH
pattern. In addition, the results of the deconvolution
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123analysis also revealed (moderately in two) increased GH
secretion in 3 patients, consistent with a high incidence of
GH excess. Indeed, IGF-I concentrations and the SD scores
were elevated in these patients, but clinical symptoms were
not apparent in two individuals. Other indirect biochemical
clues of hormone cosecretion were signiﬁcant cross-cor-
relations between TSH and GH (3 out of 5 patients), and
between TSH and prolactin (5 out of 5 patients) and the
phase delay of TSH and PRL diurnal rhythms. Somewhat
unexpectedly, a signiﬁcant correlation between TSH and a-
subunit was found in only two patients, one of whom had
clinically severe acromegaly. The lack of correlation
between TSH and a-subunit suggests that their secretion is
not coordinately regulated in the thyrotrope or that some
tumors may consist of a mixed population of thyrotropes
and purely a-subunit-secreting cells [47].
Recent histological studies of the pituitary gland have
revealed that growth hormone-secreting cells form a large-
scale network. This functional three-dimensional GH-net-
work consists of cells linked with focal adherent junctions,
shows robustness across the lifespan despite reversible
plasticity of the architecture, for instance at puberty when
GH secretion is ampliﬁed [48]. Such a network can pro-
duce rapid and synchronized hormone pulses in response to
physiological needs. If a similar network exists for thyro-
tropes, disruptions of functional organization in TSH
adenomas could explain disorganized TSH secretion, as
here observed with increased ApEn in concert with the
increased burst frequency. In addition, folliculo-stellate
cells might be involved coordinating hormone secretion in
the three-dimensional network [49]. These cells participate
in scavenger activity, paracrine regulation of endocrine
cells, as a source of stem cells and large-scale intercellular
communication by means of long cytoplasmatic processes
and gap junctions that mediate intercellular Ca
2? waves
[49–53]. Observed loss of folliculostellate cells might thus
contribute to abnormal hormone secretion patterns by
pituitary adenomas.
In summary, TSH secretion by thyrotropinomas is
characterized by increased pulse frequency with normal
interpulse variability, decreased secretory regularity,
enhanced hormone release and a delayed phase of the
diurnal rhythm. In addition, GH and prolactin secretion
also exhibit various abnormalities, ranging from decreased
regularity to overt hypersecretion. We hypothesize that
aberrant secretory characteristics are caused by histological
and cellular alterations of the network of thyrotrophic
tumor cells.
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